Q-omics provides the consensus-scored RBM12B profile across patient tissues and cancer cell-line models. RBM12B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RBM12B is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RBM12B protein abundance shows 26,706 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, HNSC, and GBM as cancer lineages where RBM12B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM12B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM12B survival associations across molecular data types. RBM12B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM12B RNA expression–survival associations across cancer types. High RBM12B expression shows unfavorable associations in LIHC, CESC, ACC and LUSC, but favorable associations in UCS and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for RBM12B RNA expression.
This table summarizes RBM12B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RBM12B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM12B shows lower tumor expression in THCA and higher tumor expression in HNSC, STAD, LIHC, LUSC and BLCA. The HNSC box plot shows higher RBM12B RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with RBM12B in patient tissues and cancer cell lines. In patient samples, RBM12B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM12B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
